GlassScriptPhysician profile
Jyotsna Ganta
NPI 1528402260
$3,773.45
in general payments reported to CMS, 2019-2025
27 companies · $1,717 in 2025
The $1,717 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $137 · 2024: $1,919 · 2025: $1,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,773.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $480.28 | 2023-2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $353.41 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $330.38 | 2023-2025 | |
| Novo Nordisk INC | $317.93 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $314.99 | 2023-2025 | Veozah |
| Amgen INC. | $303.39 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Lilly USA, LLC | $253.65 | 2023-2025 | Zepbound, Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $223.42 | 2024-2025 | |
| Abbvie INC. | $199.55 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $137.58 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.90 | 2023-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $93.73 | 2024 | Spravato |
| Novartis Pharmaceuticals Corporation | $82.61 | 2025 | |
| Esperion Therapeutics, INC. | $80.37 | 2024-2025 | Nexletol |
| Exact Sciences Corporation | $71.10 | 2025 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $60.02 | 2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Xeris Pharmaceuticals, INC. | $51.58 | 2024 | Gvoke Hypopen |
| Boston Scientific Corporation | $44.80 | 2024-2025 | Watchman Flx, General - Pain Management |
| Idorsia Pharmaceuticals US INC | $42.37 | 2023-2024 | Quviviq |
| Corcept Therapeutics | $34.99 | 2024 | Korlym |
| Dexcom, INC. | $31.36 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $27.66 | 2025 | |
| Ascensia Diabetes Care US INC. | $23.15 | 2024 | |
| Scilex Pharmaceuticals INC. | $21.80 | 2024 | |
| Abbott Laboratories | $21.52 | 2025 | Id Now Instrument |
| Lucid Diagnostics INC. | $21.41 | 2024 | |
| Seqirus USA INC | $19.50 | 2025 | Flucelvax, Fluad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jyotsna Ganta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.